Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report
- 170 Downloads
Cyproterone acetate (CPA) is an antiandrogenic drug which has recently been recognized to promote the occurrence and growth of intracranial meningiomas. Nomegestrol acetate (NOMAC) is a widely used progestin-like drug that could be suggested as an alternative for patients taking CPA. We report a case of CPA-related meningioma for which relay from CPA to NOMAC led to further tumor growth and cessation of NOMAC-induced tumor shrinkage. We suggest NOMAC can have a similar effect than CPA on meningiomas. The use of NOMAC as replacement for CPA in the presence of a meningioma should be discouraged until further evidence becomes available on the role of NOMAC in such instances.
KeywordsCyproterone acetate Nomegestrol acetate Meningioma Hormone therapy
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The patient has consented to the submission of the case report for submission to the journal.
- 16.Froelich S, Dali-Youcef N, Boyer P, Kehrli P, Maitrot D, Auwerx J (2008) Does cyproterone acetate promote multiple meningiomas? 10th European Congress of Endocrinology, vol 16 Berlin, 158Google Scholar
- 20.Lee KL, Terris MK (2003) Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma. Urology 62:351Google Scholar